MR-guided transurethral US ablation viable for treating prostate cancer

Thursday, December 4 | 10:40 a.m.-10:50 a.m. | SSQ10-02 | Room E450B
MR-guided transurethral ultrasound ablation is a feasible, minimally invasive, and safe way to treat organ-confined prostate cancer, according to research to be presented on Thursday.

Presenter Dr. Maya Mueller-Wolf, from the German Cancer Research Center in Heidelberg, and colleagues included 30 patients with biopsy-proven, low-risk prostate cancer in a phase I clinical study. Mueller-Wolf's group performed the technique using Profound Medical's PAD-105 prostate ablation device, in conjunction with a 3-tesla MR scanner from Siemens Healthcare.

The team confirmed that cancer cells were destroyed using contrast-enhanced MR immediately after the procedure and at the 12-month follow-up. Median treatment time and prostate volume were 36 minutes and 44 mL, respectively.

The procedure was well-tolerated by all patients, and there were no intraoperative complications, according to the researchers. They further confirmed that the treatment was successful with a median prostate-specific antigen (PSA) decrease from 5.8 ng/mL to 0.7 ng/mL at one month after the procedure in 24 patients.

Whole-gland ablation can be safely and accurately performed using the technology, the group concluded.

Page 1 of 505
Next Page